auristatin E antibody-drug conjugate (Seattle Genetics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameauristatin E antibody-drug conjugate (Seattle Genetics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate

Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 modulatorsCD70 antigen inhibitors

TargetsTumor necrosis factor receptor superfamily member 8CD70 antigen

Therapy Area/IndicationsNeutropeniaNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSeagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSeagen Inc

Active IndicationsN/A

Inactive IndicationsNeutropeniaNeoplasms

Other Information

ATC CodeN/A